Biological
Tisagenlecleucel clinical trials
Also written CART-19, CTL019 and Kymriah.
- studies test it
- 42
- open now
- 6
- in phase 3
- 5
- first study started
- 2010
Keep track of what changes. Save the tisagenlecleucel studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Combined with it in one product
Studies by the year they started
42 studies that test it; most in 2016 (7)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 7 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 16
- Phase 2
- 25
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 24
Novartis Pharmaceuticals (15) · University of Pennsylvania (10) · Memorial Sloan Kettering Cancer Center (1) · Masonic Cancer Center, University of Minnesota (1) · Peter MacCallum Cancer Centre, Australia (1) · Sara V. Latorre (1) · NeoImmuneTech (1) · Matthew J. Frigault, M.D. (1)
Often tested with
Tested in the same studies.
Axicabtagene ciloleucel (3) · Fludarabine (3) · Cyclophosphamide (3) · Lisocabtagene maraleucel (3) · Ibrutinib (2) · Brexucabtagene autoleucel (1) · Idecabtagene vicleucel (1) · Efineptakin alfa (1)
Studies
Open first, then newest update. How each study uses tisagenlecleucel is read from its arms, and is right about nine times in ten.
Testing it · 42
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingPhase 2SWOG Cancer Research NetworkNCT05633615Written as Tisagenlecleucel
- Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell LymphomaRecruitingPhase 1Nathan DenlingerNCT07676877Written as Tisagenlecleucel
- CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for LupusRecruitingPhase 1/2Children's Hospital of PhiladelphiaNCT06839976Written as CART19
- Study of Out of Specification for TisagenlecleucelRecruitingPhase 3Novartis PharmaceuticalsNCT04094311Written as CTL019
- CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and LymphomaRecruitingPhase 1/2University of Sao PauloNCT06101381Written as CART-19
- CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)RecruitingPhase 1/2Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdNCT03896854Written as CART-19
- Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive PatientsActive, not recruitingPhase 2Novartis PharmaceuticalsNCT03876769Written as CTL019
- Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell TherapyCompletedPhase 1NeoImmuneTechNCT05075603Written as Tisagenlecleucel
- Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular LymphomaCompletedPhase 2Novartis PharmaceuticalsNCT03568461Written as tisagenlecleucel
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular LymphomaActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05888493Written as Tisagenlecleucel
- A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)Active, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05460533Written as Tisagenlecleucel
- MT2017-45: CAR-T Cell Therapy for Heme MalignanciesActive, not recruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT03642626Written as KYMRIAH
- Tisagenlecleucel In Primary CNS LymphomaCompletedPhase 1Matthew J. Frigault, M.D.NCT04134117Written as Tisagenlecleucel
- Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell LymphomaActive, not recruitingPhase 2Peter MacCallum Cancer Centre, AustraliaNCT04234061Written as ibrutinib and Tisagenlecleucel
- Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to TherapyActive, not recruitingPhase 2Sara V. LatorreNCT04778579Written as ARI-0001 cells
- Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma PatientsCompletedPhase 2Novartis PharmaceuticalsNCT03610724Written as Tisagenlecleucel
- Study of Efficacy and Safety of CTL019 in Adult DLBCL PatientsCompletedPhase 2Novartis PharmaceuticalsNCT02445248Written as Tisagenlecleucel
- Study of Efficacy and Safety of CTL019 in Pediatric ALL PatientsCompletedPhase 2Novartis PharmaceuticalsNCT02435849Written as CTL019
- CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to ChemotherapyCompletedPhase 1University of PennsylvaniaNCT01029366Written as CART-19
- Dose Optimization Trial of CD19 Redirected Autologous T CellsCompletedPhase 2University of PennsylvaniaNCT01747486Written as CART-19
See all 42 studies that test tisagenlecleucel →
Given in every arm · 3 — tisagenlecleucel is usual care beside what is tested
- Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell MalignanciesRecruitingPhase 1Stanford UniversityNCT06408194Written as Tisagenlecleucel
- Ph I/II Study of E7777 Prior to CAR-T for R/R LBCLSuspendedPhase 1/2Masonic Cancer Center, University of MinnesotaNCT04855253Written as Tisagenlecleucel
- Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS StudyCompletedEarly Phase 1Emory UniversityNCT04890236Written as Tisagenlecleucel
Codes
What other systems call tisagenlecleucel · ClinicalTrials.gg INT000899
- MeSH (NLM) C000626284tisagenlecleucelConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) Q6C9WHR03OTISAGENLECLEUCELConfirmed FDA, NLM, Wikidata
- RxNorm 1986438Confirmed FDA, Wikidata
- Wikidata Q30314624tisagenlecleucelConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C102758TisagenlecleucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000626284 | tisagenlecleucel | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | Q6C9WHR03O | TISAGENLECLEUCEL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1986438 | — | Confirmed FDA, Wikidata |
| Wikidata | Q30314624 | tisagenlecleucel | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C102758 | Tisagenlecleucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.